SeQure Dx

The company primarily serves clients in the biotech and pharmaceutical industries, particularly those involved in developing CRISPR-based therapeutics. These clients range from preclinical researchers to clinical developers who need to ensure their gene editing techniques are both effective and safe.

SeQure Dx operates in the rapidly growing market of gene editing and cell and gene therapy research. This market is driven by the increasing interest in developing new therapies for genetic disorders, cancers, and other diseases.

The business model of SeQure Dx is service-based. They partner with other companies, such as Synthego and KromaTiD, to offer integrated and comprehensive off-target analysis services. These partnerships allow SeQure Dx to provide a full suite of diagnostic services that support the entire lifecycle of gene editing projects—from initial research to clinical trials and eventual patient therapies.

SeQure Dx makes money by charging fees for their analytical services. These fees are based on the complexity and scope of the analysis required by their clients. By offering scalable solutions that can be tailored to individual or population-level insights, SeQure Dx ensures that their services are accessible to a wide range of clients, from small research labs to large pharmaceutical companies.

In summary, SeQure Dx is a key player in the gene editing field, providing essential off-target analysis to ensure the safety and efficacy of new genetic therapies.